The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK

Depo-Provera 对 HIV 易感性、免疫激活和 PrEP PK 的影响

基本信息

  • 批准号:
    8588047
  • 负责人:
  • 金额:
    $ 41.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-19 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Worldwide, there were over 6,000 new HIV infections a day in 2010 and almost half were among women. Injectable contraceptives have been associated with a 2-4 fold increased risk of HIV acquisition in some observational studies. Yet, these injectable progestin's, like Depo-Provera" (medroxyprogesterone acetate [MPA]), are the second most common contraceptive method used by women worldwide. Animal data support the increased HIV risk. Prospective clinical evidence is lacking. If injectable contraceptives increase HIV susceptibility, and if heterosexual women at high-risk for HIV infection desire to continue injectable contraception use, effective HIV prevention methods such as pre-exposure prophylaxis (PrEP) become even more important. For women at high risk of HIV infection, PrEP with daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) can substantially reduce the risk of HIV acquisition. In July 2012, the U.S. Food and Drug Administration approved TDF/FTC for PrEP and emphasized that effectiveness is strongly correlated with drug concentrations. Individuals with lower than expected drug concentrations had higher HIV seroconversion rates. While adherence to daily TDF/FTC is thought to explain the differences in plasma concentrations, our preliminary data indicate that sex steroid hormones may also contribute to lower antiretroviral concentrations and increase HIV susceptibility. Given these findings, we hypothesize that the injectable contraceptive, MPA, increases HIV susceptibility through inducing immune activation and increasing HIV co-receptor expression on genital tract target cells. Further, we hypothesize that MPA decreases effective TDF/FTC concentrations through increased renal clearance secondary to increased glomerular filtration and/or up-regulation of progesterone-sensitive drug transporters on CD4+T and kidney cells, as well as alteration of drug phosphorylation and activation in CD4+T cells. Our specific aims are to: (1) determine the effect of MPA on HIV susceptibility in blood, cervical tissue, and cervicovaginal fluid; and (2) quantify the impact of MPA on TDF/FTC in vivo pharmacokinetics and, secondarily, in vitro pharmacodynamics in blood, cervical tissue, and cervicovaginal fluid. There is an urgent need to address this dilemma regarding injectable contraceptives in women at risk for HIV infection. Does the use of injectable MPA, a highly effective and inexpensive birth control option, increase HIV acquisition risk and diminish the HIV protective effects of TDF/FTC PrEP? This information is needed to inform women's contraceptive choice, especially among those at high risk of HIV.
描述(由申请人提供):2010年,全球每天有6,000多名新的艾滋病毒感染者,其中近一半是妇女。在一些观察性研究中,注射避孕药与艾滋病毒感染风险增加2-4倍有关。然而,这些可注射的孕酮,如Depo-Provera(醋酸甲羟孕酮[MPA]),是全世界妇女使用的第二种最常见的避孕方法。动物数据支持艾滋病毒风险增加。缺乏前瞻性临床证据。如果注射避孕药增加了艾滋病毒的易感性,如果处于艾滋病毒感染高风险的异性恋妇女希望继续使用注射避孕药,有效的艾滋病毒预防方法,如暴露前预防(PrEP)变得更加重要。对于HIV感染高风险的女性,每日口服富马酸替诺福韦酯/恩曲他滨(TDF/FTC)的PrEP可以大大降低HIV感染的风险。2012年7月,美国食品和药物管理局批准TDF/FTC用于PrEP,并强调有效性与药物浓度密切相关。低于预期药物浓度的个体具有较高的HIV血清转换率。虽然坚持每日TDF/FTC被认为可以解释血浆浓度的差异,但我们的初步数据表明,性类固醇激素也可能有助于降低抗逆转录病毒药物浓度并增加HIV易感性。鉴于这些发现,我们假设注射避孕药MPA通过诱导免疫激活和增加生殖道靶细胞上的HIV辅助受体表达来增加HIV易感性。此外,我们假设MPA通过增加继发于肾小球滤过增加的肾清除率和/或上调CD 4 +T细胞和肾细胞上的孕酮敏感性药物转运蛋白,以及改变CD 4 +T细胞中的药物磷酸化和活化,降低有效TDF/FTC浓度。我们的具体目标是:(1)确定MPA对血液、宫颈组织和宫颈阴道液中HIV易感性的影响;(2)量化MPA对TDF/FTC体内药代动力学的影响,其次是对血液、宫颈组织和宫颈阴道液中体外药效学的影响。迫切需要解决在有感染艾滋病毒风险的妇女注射避孕药方面的这一难题。使用注射型MPA(一种高效且廉价的避孕选择)是否会增加HIV感染风险并降低TDF/FTC PrEP的HIV保护作用?需要这些信息来指导妇女,特别是艾滋病毒高风险妇女选择避孕方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig Walter Hendrix其他文献

Craig Walter Hendrix的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig Walter Hendrix', 18)}}的其他基金

Phosphorylation of Drugs in Colonic Tissue
结肠组织中药物的磷酸化
  • 批准号:
    10653625
  • 财政年份:
    2022
  • 资助金额:
    $ 41.31万
  • 项目类别:
Population Pharmacokinetic Modeling and Clinical Trial Simulation to optimize HIV Prevention in Pregnancy and Postpartum
群体药代动力学模型和临床试验模拟可优化妊娠期和产后的艾滋病毒预防
  • 批准号:
    10316144
  • 财政年份:
    2021
  • 资助金额:
    $ 41.31万
  • 项目类别:
Development of Rectal Enema As Microbicide (DREAM)
直肠灌肠剂作为杀菌剂的开发(DREAM)
  • 批准号:
    9088326
  • 财政年份:
    2014
  • 资助金额:
    $ 41.31万
  • 项目类别:
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film
UC781 的探索性药代动力学
  • 批准号:
    8660270
  • 财政年份:
    2014
  • 资助金额:
    $ 41.31万
  • 项目类别:
Clinical optimization of a tenofovir enema and adherence tracking
替诺福韦灌肠和依从性跟踪的临床优化
  • 批准号:
    8768695
  • 财政年份:
    2014
  • 资助金额:
    $ 41.31万
  • 项目类别:
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film
UC781 的探索性药代动力学
  • 批准号:
    8471644
  • 财政年份:
    2013
  • 资助金额:
    $ 41.31万
  • 项目类别:
Clinical Laboratory & Biomarker Core
临床实验室
  • 批准号:
    10458362
  • 财政年份:
    2012
  • 资助金额:
    $ 41.31万
  • 项目类别:
Pre-Phase I Evaluations
第一阶段前期评估
  • 批准号:
    8404840
  • 财政年份:
    2012
  • 资助金额:
    $ 41.31万
  • 项目类别:
Clinical Laboratory & Biomarker Core
临床实验室
  • 批准号:
    10612986
  • 财政年份:
    2012
  • 资助金额:
    $ 41.31万
  • 项目类别:
Laboratory and Biomarkers Core
实验室和生物标志物核心
  • 批准号:
    10153642
  • 财政年份:
    2012
  • 资助金额:
    $ 41.31万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 41.31万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 41.31万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 41.31万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 41.31万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 41.31万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 41.31万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 41.31万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 41.31万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 41.31万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 41.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了